Vanguard reports 5.04% stake in Jazz Pharmaceuticals
Jazz Pharmaceuticals PLC ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,103,522 shares of common stock, representing 5.04% of the class.
Rhea-AI Filing Summary
Jazz Pharmaceuticals PLC ownership filing shows Vanguard Capital Management reports beneficial ownership of 3,103,522 shares of common stock, representing 5.04% of the class. The filing lists sole voting power for 455,189 shares and sole dispositive power over 3,103,522 shares. The signature date on the filing is 04/30/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports a 5.04% beneficial stake with dispositive control of 3,103,522 shares.
Schedule 13G shows Vanguard Capital Management as the reporting entity with sole dispositive power over 3,103,522 shares and sole voting power over 455,189 shares. The filing includes affiliates that exercise voting or dispositive power for managed funds and accounts.
Because this is a passive ownership disclosure under Schedule 13G, it indicates a sizable institutional holding but does not by itself signal active engagement or trading intent. Subsequent filings could change voting or disposition figures.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power financial
sole voting power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard Capital Management report in JAZZ?
How many votes does Vanguard control in the JAZZ filing?
When was the Schedule 13G for JAZZ signed by Vanguard?
Does the Schedule 13G indicate Vanguard is an active investor in JAZZ?
Which Vanguard entities are referenced in the JAZZ filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.